- Dr Adie Viljoen, Dr Mohamed Elnaggar
Sponsored
This Masterclass was developed in collaboration with the National Amyloidosis Centre, London UK
Amyloidosis is rapidly gaining recognition as a previously under-diagnosed cause of cardiomyopathy and heart failure. Here, experts from the National Amyloidosis Centre – the only centre in the UK specialising in the management of the condition – provide an overview of its prevalence, symptoms and key treatment principles.
Amyloidosis is rapidly gaining recognition as a previously under-diagnosed cause of cardiomyopathy and heart failure. Here, experts from the National Amyloidosis Centre – the only centre in the UK specialising in the management of the condition – provide an overview of its prevalence, symptoms and key treatment principles.
Masterclass
Dr Sarah Hudson and Charles Lowe discuss the latest advancements in digital innovation both supporting and challenging cardiology clinicians in the UK. Topol Fellow, Dr Hudson shares her wealth of knowledge and experience as a cardiologist with Charles Lowe, who’s worked in the digital healthcare space for over 25 years.
In this fascinating conversation, we discover what is happening in cardiology clinics and what the future might hold for cardiologists. Look out for future videos covering these topics in more detail:
Dr Sarah Birkhoelzer and Dr Ahmed Alsobhi review the latest trial data revealed at this year's ESC congress and discuss the 2025 guideline updates. What does this all mean in real terms for UK clinicians?
In recent years, there has been a switch to direct oral anticoagulants (DOACs) as first-line thrombosis prevention, with fewer people started on a vitamin K antagonist, such as warfarin. This has led to an increase in number of people taking anticoagulants and, therefore, an increased risk of intracranial and intracerebral haemorrhages and gastrointestinal bleeds. Listen to Richard Buka, Clinical Research Fellow Institute of Cardiovascular Sciences at the University of Birmingham, discuss the challenges clinical teams face in the reversal of these drugs. He explores the findings of recent trials of Andexanet alfa and considers how effective these drugs really are and what it means in practice.
The increasing survival rate of cancer patients along with the increase in the toxicity profile of treatments has resulted in a growing demand for specialist cardio-oncology care. Listen to Priya Reehal, Clinical Nurse Specialist at the Royal Brompton Hospital Centre of Excellence for Cardio-oncology, discuss her role, present the findings of a decade-long study into the number of patients referred for cancer therapy–related cardiac dysfunction, and explain why we need more cardio-oncology centres of excellence across the UK.
